Clinical and Translational Cancer Control Research Training Program

临床和转化癌症控制研究培训计划

• 批准号: 9788901
• 负责人: Michelle C Janelsins
• 金额: $ 35.65万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9788901
• 关键词: Cancer Control Research; Clinical; Training Programs

ABSTRACT This is a third competing renewal of the Clinical and Translational Cancer Control Research Training Program (CCRTP) R25T, transitioning into the T32 mechanism, led by Gary Morrow, PhD, MS, and Michelle Janelsins, PhD, MPH, of the University of Rochester (UR). The primary aim of the 2- to 3-year CCRTP is to provide MD and PhD trainees with the tools and experiences necessary to establish careers as outstanding independent investigators in cancer control research. This program fills an unmet need to train the next generation of cancer control investigators. As improvements in cancer treatments increase survival rates, there are 20 million cancer survivors and counting; these survivors continue to experience ongoing side effects that negatively impact quality of life. Thus, there is a greater need to better understand the numerous debilitating side effects of cancer treatment and develop interventions. The program combines didactic and “hands-on” research training activities. Dr. Janelsins, a former graduate of the CCRTP, formally joined Dr. Morrow as MPI in 2018 to enhance the translational science component of the CCRTP, providing synergy with Dr. Morrow’s expertise in clinical trials. For example, a number of recent trainees have focused on biologic mechanisms of intervention effects to alleviate side effects, or understanding biologic, medical, and psychologic risk factors for those who may develop side effects. Dr. Morrow and Dr. Janelsins are joined by 21 multidisciplinary, outstanding, experienced R01- funded mentors and 3 junior mentors with NCI K Awards from 12 academic departments, and exceptional infrastructure support from the NCI-funded Community Oncology Research Program (NCORP) Research Base, the UR Clinical and Translational Sciences Institute (CTSI), among others, as well as unparalleled institutional support from which to draw upon expertise to conduct and publish independent analyses and develop their own independent clinical and translational research projects. These research experiences are complemented by completion of a Master of Science (MS or MPH) degree focused in clinical investigation, epidemiology, translational research, health services, or data science. For our last 5 classes, 82 applicants (50 males/32 females, 18 MD/63 PhD, 8 minority) have been evaluated; 27 were invited for on-site interviews and 15 of the 16 who were offered positions accepted, including 5 minority applicants. They have produced 145 unique manuscripts, obtained several outstanding research awards, and earned $4.1 million in research funding. To date, 29 of the 31 trainees who have completed the program (last 15 years) have obtained tenure-track academic positions, and achieved a total of $63 million in independent funding, including 25 R-grants. Throughout our history, we have recruited approximately 50% women and 30% minority trainees. A majority (94%) of our trainees are still in academic cancer research-focused careers at Assistant (15), Associate (11), and Full (3) Professor level; some have also become leaders or directors of major programs within cancer centers. Our next renewal will continue to build upon this momentum of success.

摘要 这是临床和转化性癌症控制研究培训计划的第三次竞争性更新 (CCRTP)R25T，过渡到T32机制，由Gary Morrow博士、MS和Michelle Janelsins领导， 罗切斯特大学(UR)博士，公共卫生硕士。2-3年CCRTP的主要目标是提供MD 和博士生培训，拥有必要的工具和经验，以建立作为杰出的独立职业生涯 癌症控制研究的研究人员。这一计划填补了培训下一代癌症患者的未得到满足的需求 特工局的调查员。随着癌症治疗方法的改进提高了存活率，目前有2000万癌症患者 幸存者和越来越多的人；这些幸存者继续经历着负面影响质量的持续副作用 生活的一部分。因此，更有必要更好地了解癌症的许多令人衰弱的副作用。 治疗和制定干预措施。该计划结合了说教和实践的研究培训活动。 Janelsins博士曾毕业于CCRTP，于2018年正式加入Morrow博士担任MPI，以加强 CCRTP的翻译科学组成部分，与莫罗博士在临床试验方面的专业知识提供协同作用。 例如，最近的一些受训者将重点放在干预效应的生物机制上。 减轻副作用，或了解生物、医学和心理风险因素对那些可能发生 副作用。莫罗博士和贾内尔辛斯博士与21名多学科、杰出、经验丰富的R01- 资助导师和3名初级导师，获得来自12个学术部门的NCI K奖，并具有卓越的 NCI资助的社区肿瘤学研究计划(NCORP)研究基地的基础设施支持， UR临床和翻译科学研究所(CTSI)等，以及无与伦比的机构 提供支持，以利用专业知识进行和发布独立分析并开发自己的分析 独立的临床和转化性研究项目。这些研究经验还得到了以下补充 完成临床调查、流行病学、 翻译研究、健康服务或数据科学。在我们最后的5个班，82名申请者(50名男性/32名 女性，18名医学博士/63名博士，8名少数民族)进行了评估；27名受邀参加了现场面试，其中15名 16人被录取，其中包括5名少数族裔申请者。他们制作了145个独特的 手稿，获得了几个杰出的研究奖，并获得了410万美元的研究资金。至 截至目前，在31名完成该计划的学员中(过去15年)，有29人获得了终身教职 这些职位共获得6300万美元的独立资金，其中包括25笔R-赠款。在整个我们的 历史上，我们招募了大约50%的妇女和30%的少数民族实习生。我们的大多数实习生(94%) 仍在助教(15人)、副教授(11人)和全职教授(3人)从事以癌症研究为重点的学术职业 一些人还成为癌症中心内主要项目的负责人或主任。我们的下一次更新 将继续在这一成功势头的基础上继续发展。